The tyrosine kinase inhibitor Gleevec, currently used to treat cancers such as chronic myeloid leukemia, can also function as an antiviral drug to treat poxvirus infections (pages 731–739).
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents
BMC Pharmacology and Toxicology Open Access 04 December 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Deininger, M. et al. Blood 105, 2640–2653 (2005).
Ren, R. Nat. Rev. Cancer 5, 172–183 (2005).
Pardanani, A. & Tefferi, A. Blood 104, 1931–1939 (2004).
Reeves, P.M. et al. Nat. Med. 11, 731–739 (2005).
Smith, G.L. & Law, M. Vir. Res. 106, 189–197 (2004).
Frischknecht, F. et al. Nature 401, 926–929 (1999).
Newsome, T.P. et al. Science 306, 124–129 (2004).
Ward, B.M & Moss, B. J. Virol. 78, 2486–2493 (2004).
Andrade, A.A. et al. Biochem. J. 381, 437–446 (2004).
Yang, H. et al. J. Clin. Invest. 115, 379–387 (2005).
McFadden, G. Nat. Rev. Immunol. 3, 201–213 (2005).
O'Hare, T. et al. Cancer Cell 7, 117–119 (2005).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McFadden, G. Gleevec casts a pox on poxviruses. Nat Med 11, 711–712 (2005). https://doi.org/10.1038/nm0705-711
Issue Date:
DOI: https://doi.org/10.1038/nm0705-711